论文部分内容阅读
目的探讨维格列汀联合二甲双胍治疗2型糖尿病的临床疗效及其安全性。方法选取辽阳市第二人民医院2015年2月—2016年3月收治的2型糖尿病患者100例,采取随机双盲法分为对照组和试验组,各50例。对照组患者给予二甲双胍加量治疗,试验组患者给予采取维格列汀联合二甲双胍治疗。比较两组患者的糖化血红蛋白、空腹血糖及餐后2 h血糖,并观察比较药物不良反应发生情况。结果试验组患者糖化血红蛋白高于对照组,空腹血糖及餐后2 h血糖低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论二甲双胍联合维格列汀治疗2型糖尿病效果明显,可有效控制血糖,不良反应少,安全性高。
Objective To investigate the clinical efficacy and safety of vegliptin in combination with metformin in the treatment of type 2 diabetes mellitus. Methods 100 cases of type 2 diabetic patients admitted to Liaoyang Second People’s Hospital from February 2015 to March 2016 were randomly divided into control group and experimental group with 50 cases in each group. Patients in the control group were treated with metformin, and patients in the test group were treated with vegliptin and metformin. HbAlc, fasting blood glucose and 2-hour postprandial blood glucose were compared between the two groups, and the occurrence of adverse drug reactions were observed and compared. Results The HbA1c in the experimental group was higher than that in the control group. The fasting blood glucose and 2 h postprandial blood glucose were lower than those in the control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Metformin combined with vildagliptin is effective in treating type 2 diabetes mellitus, which can effectively control blood sugar with less adverse reactions and high safety.